Delta, Kelowna, BC – May 6, 2021 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Investor Ideas Potcasts #560, Cannabis News and Stocks on the Move; (CSE: XTRX), (TSXV: MUSH), (NASDAQ: SNDL), (CSE: EASY), (CSE: TRUL)
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com “Potcast” featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
Today’s podcast is sponsored by Phyto Extractions Inc. (CSE:XTRX), an agricultural-scale cannabis extraction, distillation and product manufacturer located in Langley, BC at its co-located Health Canada Licensed Standard Processing (extraction, no cultivation), Sales (extracts, topicals, and edibles) through Adastra Labs Inc. and Analytical Testing Laboratory through Chemia Analytics Inc. Adastra Labs also has a pending Health Canada R&D license amendment.
In today’s podcast we look at a few public company announcements.
Sundial Growers Inc. (NASDAQ: SNDL) and Inner Spirit Holdings Ltd. (CSE: ISH) (OTCQB: INSHF) announced that they have entered into an arrangement agreement pursuant to which Sundial will acquire all of the issued and outstanding common shares of Inner Spirit for total consideration of approximately $131 million. The combined company will continue to focus on providing quality cannabis to consumers through a responsible and disciplined approach while creating enduring value for shareholders.
Under the terms of the Agreement, Inner Spirit’s shareholders will receive, for each Inner Spirit common share held, (i) $0.30 in cash and (ii) 0.0835 of a Sundial common share (representing $0.09 per Inner Spirit common share based on the 10-day volume-weighted average price (“VWAP”) of Sundial common shares on the Nasdaq Capital Market), for total consideration of $0.39 per Inner Spirit common share. The purchase price of $0.39 per Inner Spirit common share represents a premium of 54.8% to the 10-day VWAP of Inner Spirit common shares on the Canadian Securities Exchange (the “CSE”) and a premium of 62.5% to the closing price of Inner Spirit common shares on the CSE on May 4, 2021. The Transaction has been unanimously approved by the Boards of Directors of Sundial and Inner Spirit and is expected to close early in the third quarter of 2021.
The Transaction is expected to provide modest synergies and economies of scale due to the different business models of Sundial and Inner Spirit.
“Sundial becomes a stronger and more diverse cannabis company by acquiring Inner Spirit and the Spiritleaf retail store network,” said Zach George, Chief Executive Officer of Sundial. “Inner Spirit has successfully created a franchise-based retail network that has grown from coast to coast and offers a differentiated and premium in-store experience to consumers. Our shared Albertan roots and commitment to data-driven consumer insights make for an ideal partnership. Sundial’s capital base will enable us to support continued expansion and deepen the capabilities of the Spiritleaf retail brand.”
“Sundial is the ideal company to acquire Inner Spirit and support the future development of the Spiritleaf retail cannabis brand,” said Darren Bondar, Founder, President and Chief Executive Officer of Inner Spirit. “The Sundial team has shown a strong commitment to our management team, franchise partners and employees as well as our growth ambitions. The combination will enable us to further expand our position as the country’s leading retail cannabis brand for customers and communities and will open up new market opportunities to us. We’re also very pleased Inner Spirit shareholders will be able to participate in our future success through an ongoing equity ownership.”
In just over two years, the Spiritleaf retail network has grown to become Canada’s largest single brand retailer with 86 stores operating in British Columbia, Alberta, Saskatchewan, Ontario, and Newfoundland and Labrador. Spiritleaf’s franchised and corporate stores have created deep ties within their local communities and served 2.3 million guests in 2020. The retail brand has earned a reputation as a knowledgeable and trusted source of recreational cannabis while offering a premium consumer experience. Spiritleaf opened its 86th store on April 28, 2021 in Edmonton, Alberta and is projected to exceed the 100-store milestone in the summer of 2021.
SpeakEasy Cannabis Club Ltd. (CSE: EASY), a holder of a federal licence to cultivate, process and sell cannabis under the Cannabis Act announced it is 4 months into a 6-9 month application process to receiving its Narcotics Dealers License (“NDL”) in-order to develop and standardize psilocybin cultivation. A NDL licenced dealer may produce, assemble, sell, provide, transport, send, deliver, import or export a controlled drug (psilocybin) if they comply with the terms and conditions of their dealer’s licence and any permit issued under the licence.
In early January this year, SpeakEasy began the application process for an NDL and a section of SpeakEasy’s processing building has been earmarked as the location for the research and development area that would house a licence referred to as an NDL. The NDL allows research, development, purchase and sales among other activities of narcotics. SpeakEasy’s intent is to acquire a full catalogue of psilocybin bearing mushroom genetics in-order to develop cultivation methods, standardize potency and develop extracted concentrated products in preparation and with the expectation of the legalization of psilocybin in the Canadian market. SpeakEasy expects to complete the extensive review process and receive its NDL later this year with the total licencing process taking between six and nine months. Upon receipt, the Company intends to immediately begin the process of preparing for the anticipation of the legal market.
Founder Marc Geen states, “Agriculture has always been the core of SpeakEasy’s business and psilocybin production is not much different. Commercial mushroom production is very similar to cannabis production, especially considering both are controlled substances and likely will fall under a similar set of regulations. We are in a great position to be able to be at the forefront of the growing psilocybin market and also apply SpeakEasy’s farming knowledge to the production of magic mushrooms adding efficiency, high-quality production at an economical costs of production.”
Compelling evidence of the therapeutic benefits of psychedelic drugs appears in multiple scientific studies. Several clinical trials are underway in the United States and worldwide to investigate the therapeutic effects of psilocybin, the active component in the fungi known as “magic mushrooms.” There is new hope for treating debilitating disorders such as depression, anxiety, post-traumatic stress disorder, anorexia, obsessive-compulsive disorder, and addictions. Multiple efficacy studies going on around the world in areas that encompass life-disrupting psychiatric and neurological conditions such as major depressive disorder (MDD), addictions, and other mental illnesses. A successful outcome could completely upend treatment protocols(2).
Total transaction consideration was $6 million satisfied through the payment of $3 million in cash and by the issuance of 60,342 subordinate voting shares of the Company. Stock price was based on 10-day VWAP from the last trading day before signing.
Trulieve CEO Kim Rivers stated, “We are pleased to complete this transaction quickly as the addition of Mountaineer achieves a significant presence for us in West Virginia. Our teams have already been at work in the state and adding Mountaineer to our portfolio provides significant potential for depth and scale. We look forward to serving West Virginia patients, and expect to be operational before the end of 2021.”
As previously announced, the Mountaineer acquisition positions Trulieve for vertical operations in West Virginia. The Mountaineer business consists of a cultivation permit and two dispensary permits in West Virginia. This transaction further extends and strengthens Trulieve’s national expansion with the ability for a full-scale operation in a new medical marijuana state.
The Good Shroom Co Inc. (TSXV: MUSH), a Quebec based company that created and manufactures functional beverages under its two brands: Teonan(R) and Velada(TM), announced that it has entered into a private labelling agreement with Good Food Market Corporation pursuant to which it will manufacture and deliver three distinct functional beverages, starting this year. TGSC’s private labelling initiative is part of a two-pronged approach to solidify its position in the growing functional mushroom industry by focusing on building its own brands and by selling and supplying privately labelled products to other companies.
“This introductory order of 3,000 units will allow us to establish a relationship with Good Food and we expect, will lead to additional ongoing orders of at least 15,000 units per product in line with the terms of our two year contract.” stated Eric Ronsse, the Chief Executive Officer, “In addition, with the recent cash injection that followed the completion of the Company’s qualifying transaction, we expect to accelerate certain initiatives for both of the Company’s mushroom-based beverage lines: the Teonan and the Velada brands.
Functional mushrooms are packed with nutrients and for thousands of years, fungi were relied on for nourishment and their medicinal benefits. In recent years, renewed interest by the scientific community led to numerous studies showing their overall health benefits and unsurprisingly, mushrooms are making an important comeback; the global functional mushroom market is expected to grow annually by 9% for the next three years and is expected to reach US$34B by 2024.”
Once again, today’s podcast is sponsored by Phyto Extractions Inc. (CSE:XTRX), an agricultural-scale cannabis extraction, distillation and product manufacturer located in Langley, BC at its co-located Health Canada Licensed Standard Processing (extraction, no cultivation), Sales (extracts, topicals, and edibles) through Adastra Labs Inc. and Analytical Testing Laboratory through Chemia Analytics Inc. Adastra Labs also has a pending Health Canada R&D license amendment.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash and others.
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
The Investorideas.com podcasts are also available on iTunes (Apple Podcasts), Audible, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio, Google Play Music and most audio platforms available.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com – News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining the AI Eye.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers.
Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Cannabis Social Media
Download our Mobile App for iPhone and Android